Xingxiang Xu Selected Research

Xingxiang Xu Research Topics

Disease

10	Neoplasms (Cancer) 12/2023 - 10/2013
10	Lung Neoplasms (Lung Cancer) 01/2022 - 10/2013
5	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2023 - 11/2020
3	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2022 - 05/2015
3	Disease Progression 01/2022 - 01/2020
2	Adenocarcinoma of Lung 09/2023 - 01/2022
2	Neoplasm Metastasis (Metastasis) 01/2022 - 05/2013
2	Aneuploidy (Aneuploid) 12/2021 - 08/2017
1	Brain Neoplasms (Brain Tumor) 01/2022
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022
1	Diarrhea 01/2022
1	Exanthema (Rash) 01/2022
1	Circulating Neoplastic Cells 12/2021
1	COVID-19 12/2020
1	Autoimmune Diseases (Autoimmune Disease) 03/2020
1	Lymphopenia (Lymphocytopenia) 01/2020
1	Thrombocytopenia (Thrombopenia) 01/2020
1	Hypoxia (Hypoxemia) 05/2019
1	Lymphangioleiomyomatosis (Lymphangiomyomatosis) 01/2019
1	Colonic Neoplasms (Colon Cancer) 08/2017
1	Pleural Effusion (Pleural Effusions) 12/2016
1	Breast Neoplasms (Breast Cancer) 05/2013

Drug/Important Bio-Agent (IBA)

3	Biomarkers (Surrogate Marker)IBA 12/2023 - 03/2020
3	MicroRNAs (MicroRNA)IBA 01/2022 - 10/2013
3	ParaffinIBA 01/2020 - 01/2017
3	Formaldehyde (Formol)FDA Link 01/2020 - 01/2017
2	RNA (Ribonucleic Acid)IBA 12/2023 - 09/2023
2	aumolertinibIBA 01/2022 - 01/2022
2	camrelizumabIBA 01/2022 - 01/2022
2	Proteins (Proteins, Gene)FDA Link 12/2021 - 05/2019
2	VimentinIBA 12/2021 - 05/2019
1	EnzymesIBA 09/2023
1	Adenosine (Adenocard)FDA LinkGeneric 09/2023
1	Tyrosine Kinase InhibitorsIBA 01/2023
1	CrizotinibIBA 01/2023
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2022
1	Programmed Cell Death 1 ReceptorIBA 01/2022
1	Class 4 Receptor-Like Protein Tyrosine PhosphatasesIBA 01/2022
1	Gefitinib (Iressa)FDA Link 01/2022
1	Circular RNAIBA 01/2022
1	Carboplatin (JM8)FDA LinkGeneric 01/2022
1	Monoclonal AntibodiesIBA 01/2022
1	Etoposide (VP 16)FDA LinkGeneric 01/2022
1	Immunoglobulins (Immunoglobulin)IBA 01/2022
1	Keratin-18 (Keratin 18)IBA 12/2021
1	Tumor Biomarkers (Tumor Markers)IBA 12/2021
1	ErbB Receptors (EGF Receptor)IBA 01/2021
1	Circulating Tumor DNAIBA 01/2021
1	osimertinibIBA 01/2021
1	CytokinesIBA 12/2020
1	CateninsIBA 11/2020
1	Neoplasm Antigens (Tumor Antigens)IBA 03/2020
1	InterferonsIBA 01/2020
1	ThioredoxinsIBA 01/2020
1	Antiviral Agents (Antivirals)IBA 01/2020
1	AerosolsIBA 01/2020
1	Troponin T (Troponin T1)IBA 01/2020
1	ProcalcitoninIBA 01/2020
1	AMP-Activated Protein KinasesIBA 01/2020
1	GTP Phosphohydrolases (GTPases)IBA 05/2019
1	Endoplasmic Reticulum Chaperone BiPIBA 05/2019
1	Glucose (Dextrose)FDA LinkGeneric 05/2019
1	Sirolimus (Rapamycin)FDA Link 01/2019
1	lipoarabinomannan (LAM)IBA 01/2019
1	Zidovudine (Retrovir)FDA LinkGeneric 08/2017
1	DNA (Deoxyribonucleic Acid)IBA 08/2017
1	Telomerase (Telomerase Reverse Transcriptase)IBA 08/2017
1	mesoglycanIBA 06/2017
1	Wnt1 ProteinIBA 01/2017
1	Small Interfering RNA (siRNA)IBA 01/2017
1	Keratin-19 (Keratin 19)IBA 12/2016
1	Untranslated RNA (Noncoding RNA)IBA 05/2013
1	Doxorubicin (Adriamycin)FDA LinkGeneric 05/2013
1	Cadherins (E-Cadherin)IBA 05/2013
1	2- (4- morpholinyl)- 8- phenyl- 4H- 1- benzopyran- 4- oneIBA 05/2013

Therapy/Procedure

5	Therapeutics 01/2022 - 01/2019
2	Drug Therapy (Chemotherapy) 12/2023 - 01/2022
1	Artificial Respiration (Mechanical Ventilation) 01/2020
1	Length of Stay 05/2015